Stock Ratings / Health Care / AMS / earnings

ACON (24) ADVB (32) BGLC (30) SERA (40) ⌘ Pro Terminal →

American Shared Hospital Services (AMS) Next Earnings Date & Expected ±8.7% Move

$1.26 -5.26% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

American Shared Hospital Services (AMS) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $8.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMS)Realized 20D OHLCV Swing Band: ±8.7%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±8.7% Swing Band

±$0.11 Expected Swing

MODEL EARNINGS SETUP GAUGE

AMS Quantitative Pre-Earnings Setup: 29/100

Trailing EPS: $4.25 • YoY Revenue Growth: -0.9%

Model Bullish Setup (29/100)Model Risk Weight (71/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$28.1M	-$1.6M	-$4.5M	18%
FY 2024	2024-12-31	$28.3M	$2.2M	-$7.8M	32.4%
FY 2023	2023-12-31	$21.3M	$610.0K	$5.7M	18%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMS)

✓Walkthrough of AMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.10%⚡ TESTING RESISTANCE

2026-10-30O $1.27H $1.28L $1.26C $1.26VOL 2.0K

RES: $1.32SUP: $1.16SMA50: $1.38SMA200: $1.61

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMS Butterfly Map → + Track AMS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMS)

Health Care Rank #961 of 1016 ⚔️ ACON vs AMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMS vs. ACON, ADVB, BGLC, SERA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, American Shared Hospital Services (AMS) ranks #961 by composite RQD confidence (29/100, grade E) and #909 by equity capitalization ($8.4M). Within this direct 5-issuer industry benchmark cohort, AMS leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with AMS at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMS ACTIVE American Shared Hospital Services	E	29/100	—	18.0%	-13.8%	-5.26%	$8.4M	Benchmark Subject
ACON Aclarion Inc.	E	24/100	—	9.0%	-35.0%	-3.43%	$5.7M	/acon-vs-ams →
ADVB Advanced Biomed Inc.	E	32/100	—	—	-9.1%	-11.41%	$4.4M	/advb-vs-ams →
BGLC BioNexus Gene Lab Corp	E	30/100	—	14.6%	-35.0%	-7.79%	$2.9M	/bglc-vs-ams →
SERA Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-ams →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000744825

In its most recent audited fiscal period (FY2025, filed 2025-12-31), American Shared Hospital Services (AMS) reported GAAP revenue of $28.1M (-0.9% vs. FY2024 revenue of $28.3M , and +31.7% cumulative change since FY2023) , GAAP net income of -$1.6M, operating cash flow of $3.1M, and free cash flow of -$4.5M (+41.6% YoY). On the balance sheet, AMS closed FY2025 with $55.5M in total assets against $0 in total debt (Altman Z-Score: 0.46, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$28.1M	-$1.6M	$3.1M	-$4.5M	$55.5M	$0
FY2024 (FY)	2024-12-31	$28.3M	$2.2M	$167.0K	-$7.8M	$60.2M	$17.3M
FY2023 (FY)	2023-12-31	$21.3M	$610.0K	$5.7M	$5.7M	—	—

3. AMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, American Shared Hospital Services (NYSE: AMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.26 (-5.26% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AMS ranks #961 in composite RQD confidence.

How does AMS compare to ACON and ADVB in the Health Care sector?

Within the Health Care sector (Medical Specialities), AMS carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -13.8%. By comparison, ACON (Aclarion Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M) and ADVB (Advanced Biomed Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -9.1%, cap $4.4M). Among the 5-stock peer group, AMS leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMS?

Per AMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000744825), American Shared Hospital Services generated $28.1M in revenue (-0.9% YoY), -$1.6M in net income, and -$4.5M in free cash flow against $55.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMS trading relative to its 50-day, 200-day, and 52-week technical levels?

AMS last traded at $1.26 (-5.26% on volume of 2,240 shares), positioning the stock -8.70% below its 50-day simple moving average ($1.38) and -21.74% below its 200-day simple moving average ($1.61). Across its 52-week range of $1.21 to $2.39, AMS sits at the 4.2% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($1.15 to $1.37).